leverages research and commercialization experience to steer the project. Dr. Curry has a pharma academic and industry background with 10 years in R&D at Astra Zeneca where he evaluated technologies from outside companies.He previously founded PharmaNova a development company with treatment for menopausal hot flashes that completed clinical trial and is expected to sell in 2014

Dr Hess has been a professor of Chemistry and Biochemistry at Cornell University for 40 years. He is an elected member of National Academy of Sciences and an Elected Fellow of the American Academy of Microbiology, Biophysics Society, and the American Academy of Arts and Sciences. Dr Hess has worked in this research area for the last fifteen years and has developed a number of innovations. His work is the basis for the formation of ADispell.

Brad has filled finance, marketing, business development, and lead roles with start-up companies. He has worked at Kodak and Xerox where he led strategy and new product launch efforts. He has since been president of a start-up company and has worked for the last nine years as a hands-on resource for start-ups in markets such as medical technology and nanotechnology regarding commercialization, launch, marketing, and profitability.

Ms. Coombs started her career overseas participating and overseeing research programs in academic environments. Susan started working with Dr. Hess in the 1970s and has grown her responsibilities to oversee that work gets accomplished in the lab and that experimental results are valid. Susan directs our in vitro program at ADispell.